Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
Long G, Larkin J, Schadendorf D, Grob J, Lao C, Márquez-Rodas I, Wagstaff J, Lebbé C, Pigozzo J, Robert C, Ascierto P, Atkinson V, Postow M, Atkins M, Sznol M, Callahan M, Topalian S, Sosman J, Kotapati S, Thakkar P, Ritchings C, Pe Benito M, Re S, Soleymani S, Hodi F. Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma. Journal Of Clinical Oncology 2024, jco2400400. PMID: 39504507, DOI: 10.1200/jco.24.00400.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsPatients treated with nivolumabOverall survivalNivolumab monotherapyMultivariate analysisPD-L1Advanced melanomaPD-L1 expression levelsFactors associated with decreased survivalLong-term overall survivalPresence of liver metastasesCox proportional multivariate analysisFactors associated with survivalLactate dehydrogenaseClinical factors associated with survivalPD-L1 expressionTreatment naive patientsMedian follow-upElevated lactate dehydrogenaseCompany-sponsored trialsAssociated with survivalUnresectable/metastatic melanomaCheckpoint inhibitorsOS ratesTreatment decision making